Invitae and Tulane University researchers found 37 percent of patients with positive germline results were not covered by testing guidelines in place at the time.
Researchers used exome capture RNA sequencing to come up with a collection of circRNAs in dozens of cancer types, including proposed prostate cancer markers.
In fiscal Q2, the firm's Diagnostics and Genomics revenues were $39.3 million, up 6 percent year over year from $37.1 million.
The latest guidelines include new language about screening individuals with BRCA mutations and the potential utility of certain biomarker tests.
The qPCR assay measures methylation of six genes and could help doctors identify aggressive vs indolent prostate cancer more accurately than PSA.
Researchers found that hypoxia was associated with elevated genomic instability in 10 tumor types and saw widespread hypoxia-associated dysregulation of miRNAs.
The firm has also begun an initiative to reduce and deliver sustainable revenue growth for 2019 to compensate for commercial challenges in the US market.
Researchers from the PROREPAIR-B study reported that men with germline BRCA2 mutations and prostate cancer had shorter cause-specific survival.
CEO Kim Popovits discussed three strategic imperatives for the coming year: increasing penetration in established markets, broadening global access, and continuing to diversify its portfolio.
The assay uses a genomic DNA signature called the metastatic potential score derived from copy number alteration analysis of specific regions of the genome.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.